MedTrace Logo

Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia

NCT03374709 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-11-01

No results posted yet for this study

Summary

To evaluate the affect Oxtellar XR (Extended Release) has on neurology patients with trigeminal neuralgia (TN), and if it impacts their quality of life.

Conditions

  • Trigeminal Neuralgia

Interventions

DRUG

Oxtellar XR 150Mg Extended Release Tablet

Oxtellar XR

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Jacquelyn Bainbridge, PharmD · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2018-12-14
Completion
2018-12-14
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03374709 on ClinicalTrials.gov